JMP Securities Believes RTI Biologics (RTIX) Still Has Room to Grow

In a report issued on March 1, David Turkaly from JMP Securities reiterated a Buy rating on RTI Biologics (RTIX), with a price target of $8. The company’s shares closed yesterday at $5.61, close to its 52-week high of $5.74.

According to, Turkaly is a 4-star analyst with an average return of 15.5% and a 65.6% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Apyx Medical Corporation, Integra Lifesciences, and Nuvectra Corporation.

The word on The Street in general, suggests a Hold analyst consensus rating for RTI Biologics.

See today’s analyst top recommended stocks >>

Based on RTI Biologics’ latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $2.07 million. In comparison, last year the company had a GAAP net loss of $7.65 million.

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RTIX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

RTI Surgical, Inc. is a global surgical implant company providing surgeons with biologic, metal and synthetic implants. It operates through the following business lines: Spine, Sports Medicine and Orthopedics, Surgical Specialties, Cardiothoracic, International, and Global Commercial.